Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization.
Roeseler E, Julius U, Heigl F, Spitthoever R, Heutling D, Breitenberger P, Leebmann J, Lehmacher W, Kamstrup PR, Nordestgaard BG, Maerz W, Noureen A, Schmidt K, Kronenberg F, Heibges A, Klingel R; Pro(a)LiFe-Study Group. Roeseler E, et al. Among authors: leebmann j. Arterioscler Thromb Vasc Biol. 2016 Sep;36(9):2019-27. doi: 10.1161/ATVBAHA.116.307983. Epub 2016 Jul 14. Arterioscler Thromb Vasc Biol. 2016. PMID: 27417585
Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study.
Leebmann J, Roeseler E, Julius U, Heigl F, Spitthoever R, Heutling D, Breitenberger P, Maerz W, Lehmacher W, Heibges A, Klingel R; Pro(a)LiFe Study Group*. Leebmann J, et al. Circulation. 2013 Dec 17;128(24):2567-76. doi: 10.1161/CIRCULATIONAHA.113.002432. Epub 2013 Sep 20. Circulation. 2013. PMID: 24056686
Real-world study: Escalating targeted lipid-lowering treatment with PCSK9-inhibitors and lipoprotein apheresis.
Spitthöver R, Röseler T, Julius U, Heigl F, Schettler VJJ, Kühn R, Leebmann J, Raabe A, Knittel M, Schürfeld C, Moesenthin M, Bernhardt WM, Röseler E, Ketteler M, Heibges A, Klingel R. Spitthöver R, et al. Among authors: leebmann j. J Clin Apher. 2019 Aug;34(4):423-433. doi: 10.1002/jca.21695. Epub 2019 Feb 28. J Clin Apher. 2019. PMID: 30817043
Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial.
Moriarty PM, Parhofer KG, Babirak SP, Cornier MA, Duell PB, Hohenstein B, Leebmann J, Ramlow W, Schettler V, Simha V, Steinhagen-Thiessen E, Thompson PD, Vogt A, von Stritzky B, Du Y, Manvelian G. Moriarty PM, et al. Among authors: leebmann j. Eur Heart J. 2016 Dec 21;37(48):3588-3595. doi: 10.1093/eurheartj/ehw388. Epub 2016 Aug 29. Eur Heart J. 2016. PMID: 27572070 Free PMC article. Clinical Trial.
CytoResc - "CytoSorb" Rescue for critically ill patients undergoing the COVID-19 Cytokine Storm: A structured summary of a study protocol for a randomized controlled trial.
Stockmann H, Keller T, Büttner S, Jörres A, Kindgen-Milles D, Kunz JV, Leebmann J, Spies C, Träger K, Treskatsch S, Uhrig A, Willam C, Enghard P, Slowinski T; CytoResc Trial Investigators. Stockmann H, et al. Among authors: leebmann j. Trials. 2020 Jun 26;21(1):577. doi: 10.1186/s13063-020-04501-0. Trials. 2020. PMID: 32586396 Free PMC article.